Fecal Microbiota Transplant for Parkinson's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether a fecal microbiota transplant (FMT) can improve symptoms in people with Parkinson's disease. Researchers believe that gut issues may significantly contribute to Parkinson’s disease, and FMT could address this. Participants will receive FMT following a 10-day course of the antibiotic vancomycin. The trial seeks individuals diagnosed with Parkinson's disease. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative treatment.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
Is there any evidence suggesting that Fecal Microbiota Transplant is likely to be safe for humans?
Research shows that fecal microbiota transplants (FMT) are generally safe. Previous studies have used FMT to treat various health issues with positive results. Most patients tolerated the procedure well, and serious side effects were uncommon. Mild side effects included stomach discomfort and diarrhea.
The FDA has approved FMT for treating certain infections, indicating a level of safety. However, since this trial is in the early stages, it focuses primarily on ensuring safety for people with Parkinson's disease. While early results are promising, the treatment is still under careful study for this new use.12345Why do researchers think this study treatment might be promising for Parkinson's?
Unlike standard Parkinson's treatments, which typically focus on managing symptoms with medications like Levodopa or dopamine agonists, Fecal Microbiota Transplant (FMT) offers a novel approach by targeting the gut microbiome. This treatment is unique because it involves transplanting beneficial bacteria from a healthy donor's stool to the patient, potentially rebalancing gut flora and influencing neurological health. Researchers are excited about FMT because it taps into the gut-brain axis, a cutting-edge area of study, and could offer benefits beyond symptom management, potentially addressing underlying factors of the disease.
What evidence suggests that Fecal Microbiota Transplant might be an effective treatment for Parkinson's Disease?
Studies have shown that fecal microbiota transplantation (FMT) can restore the balance of bacteria in the gut. This is important because gut health might influence Parkinson's disease symptoms. Early findings suggest FMT could improve quality of life and lessen symptoms for people with Parkinson's. Research has demonstrated FMT's effectiveness in other conditions by rebalancing gut bacteria, supporting the idea that it might help with Parkinson's as well. Although interest is growing, more studies are needed to confirm its effectiveness specifically for Parkinson's disease. Participants in this trial will receive FMT after a 10-day treatment with Vancomycin to evaluate its safety in adult subjects with Parkinson's disease.12367
Are You a Good Fit for This Trial?
This clinical trial is open to individuals who have been diagnosed with Parkinson's Disease (PD). It specifically excludes anyone who does not have PD.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Vancomycin Treatment
Participants receive a 10-day treatment with Vancomycin
Fecal Microbiota Transplant
Participants undergo fecal microbiota transplant procedure by colonoscopy
Post-FMT Assessment
Participants are assessed post-FMT with daily phone calls for a week and weekly phone calls thereafter
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Fecal Microbiota Transplant
Fecal Microbiota Transplant is already approved in United States, European Union, Canada for the following indications:
- Recurrent and refractory Clostridioides difficile infection
- Recurrent and refractory Clostridioides difficile infection
- Recurrent and refractory Clostridioides difficile infection
Find a Clinic Near You
Who Is Running the Clinical Trial?
ProgenaBiome
Lead Sponsor